The correction of immune disorders by extracorporeal efferent detoxication methods (EEDM) in severe community-acquired pneumonia (CAP) Source: Annual Congress 2007 - Infectious lung and pleural diseases Year: 2007
The improvement of protease-inhibitor imbalance in severe community-acquired pneumonia (CAP) by extracorporeal efferent detoxication methods (EEDM) Source: Annual Congress 2007 - Infectious lung and pleural diseases Year: 2007
Efficacy of combined therapy in severe community-acquired pneumonia (CAP) with efferent detoxication methods (EDM) vs. standard therapy by antibiotics (STA) Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005
Detection of liver function in patients with severe community-acquired pneumonia (CAP) Source: Eur Respir J 2002; 20: Suppl. 38, 15s Year: 2002
Endothelial dysfunction and its corrections in patients with severe community-aquired pneumonia (CAP) Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020
Comparison of costs of community-acquired pneumonia (CAP) treatment at patients with and without bronchial obstruction Source: Annual Congress 2011 - COPD management Year: 2011
Incidence of severe sepsis as a cause of clinical failure in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2007; 30: Suppl. 51, 42s Year: 2007
Non-invasive ventilation (NIV) in community-acquired pneumonia CAP) and severe acute respiratory failure (ARF): Effectiveness and risk factors for failure and mortality Source: Annual Congress 2011 - Recent advances in noninvasive ventilation used for treating acute respiratory failure Year: 2011
Thyroid function in community-acquired pneumonia (CAP) patients: Pattern, relationship with severity and outcomes, need for invasive mechanical ventilation and vasopressor support Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010
Use of ceftriaxone/sulbactame for treatment of mild-to-severe community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Treatment of airways disease Year: 2009
Mortality in patients with ventilator-associated pneumonia (VAP) and severe sepsis is determined by the number of organ failures Source: Annual Congress 2009 - Ventilator-associated pneumonia, severe community-acquired pneumonia and healthcare associated pneumonia Year: 2009
Acute respiratory failure (ARF) and severe sepsis (SS) in community acquired pneumonia (CAP): different outcomes? Source: Annual Congress 2009 - Impact of biomarkers in the management of community-acquired pneumonia Year: 2009
Enhanced neutrophil response in patients with chronic bronchitis and community-acquired pneumonia (CAP) Source: Eur Respir J 2002; 20: Suppl. 38, 418s Year: 2002
The peculiarity of community-acquired pneumonia (CAP) express-diagnostic by means of bacterioscopy Source: Eur Respir J 2004; 24: Suppl. 48, 413s Year: 2004
Analysis of therapy of community-acquired pneumonia (CAP) at the COPD patients Source: Annual Congress 2011 - COPD management Year: 2011
Characterization of community acquired pneumonia (CAP) with severe sepsis at diagnosis Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections Year: 2012
Definition of severity and the reasons for hospitalization (RH) in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 641s Year: 2005
"Masks" of severe pneumonia (retrospective analysis of letal severe community-acquired pneumonia (sCAP)) Source: Annual Congress 2013 –Respiratory infections: a combination of problems needing early treatment Year: 2013
Community-acquired pneumonia as a cause of acute respiratory failure (ARF) in COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 518s Year: 2005
Type of acute respiratory failure and development of ventilator-associated pneumonia (VAP) Source: Annual Congress 2009 - Ventilator-associated pneumonia, severe community-acquired pneumonia and healthcare associated pneumonia Year: 2009